Rifaximin: Difference between revisions
(Rifaximin page) |
ClaireLewis (talk | contribs) No edit summary |
||
| (8 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: Antibiotic | *Type: [[Antibiotic]] | ||
*Dosage Forms: 200, 550 | *Dosage Forms: 200, 550 | ||
*Routes of Administration: Oral | *Routes of Administration: Oral | ||
| Line 6: | Line 6: | ||
==Adult Dosing== | ==Adult Dosing== | ||
*Traveler's diarrhea, E. coli-induced: | *Traveler's diarrhea, E. coli-induced: 200mg PO tid x3 days | ||
*Hepatic encephalopathy: | *Hepatic encephalopathy: 550mg PO bid | ||
*IBS, diarrhea-predominant: | *IBS, diarrhea-predominant: 550mg PO tid x14 days | ||
**May repeat dose up to 2x if recurrent | **May repeat dose up to 2x if recurrent disease | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
===For > 12 yrs old === | ===For > 12 yrs old=== | ||
*Traveler's diarrhea, E. coli-induced: | *Traveler's diarrhea, E. coli-induced: 200mg PO tid x3 days | ||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C | ||
*[[Lactation risk categories|Lactation risk]]: | *[[Lactation risk categories|Lactation risk]]: Infant risk cannot be ruled out | ||
===Renal Dosing=== | ===Renal Dosing=== | ||
*No | *No adjustment | ||
===Hepatic Dosing=== | ===Hepatic Dosing=== | ||
*No adjustment | *No adjustment | ||
| Line 28: | Line 29: | ||
*Allergy to class/drug | *Allergy to class/drug | ||
*caution if hepatic impairment (Child-Pugh Class C) | *caution if hepatic impairment (Child-Pugh Class C) | ||
*caution if recent | *caution if recent antibiotic-associated colitis | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
| Line 34: | Line 35: | ||
*superinfection | *superinfection | ||
*C. difficile-assoc. diarrhea | *C. difficile-assoc. diarrhea | ||
*hypersensitivity | *hypersensitivity reaction | ||
*angioedema | *angioedema | ||
*anaphylaxis | *anaphylaxis | ||
| Line 50: | Line 51: | ||
==References== | ==References== | ||
<Epocrates, UpToDate> | <Epocrates, UpToDate> | ||
[[Category: | [[Category:Pharmacology]] | ||
[[Category:ID]] [[Category:GI]] | |||
Latest revision as of 22:18, 23 September 2019
Administration
- Type: Antibiotic
- Dosage Forms: 200, 550
- Routes of Administration: Oral
- Common Trade Names: Xifaxan
Adult Dosing
- Traveler's diarrhea, E. coli-induced: 200mg PO tid x3 days
- Hepatic encephalopathy: 550mg PO bid
- IBS, diarrhea-predominant: 550mg PO tid x14 days
- May repeat dose up to 2x if recurrent disease
Pediatric Dosing
For > 12 yrs old
- Traveler's diarrhea, E. coli-induced: 200mg PO tid x3 days
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk cannot be ruled out
Renal Dosing
- No adjustment
Hepatic Dosing
- No adjustment
Contraindications
- Allergy to class/drug
- caution if hepatic impairment (Child-Pugh Class C)
- caution if recent antibiotic-associated colitis
Adverse Reactions
Serious
- superinfection
- C. difficile-assoc. diarrhea
- hypersensitivity reaction
- angioedema
- anaphylaxis
- exfoliative dermatitis
Common
- peripheral edema
- nausea
- dizziness
- fatigue
Comments
See Also
References
<Epocrates, UpToDate>